Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1461-1470 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|July 16, 2015
MoFvAb: Modeling the Fv region of antibodiesAlexander Bujotzek, Angelika Fuchs, Changtao Qu, et al.
Mabs|August 6, 2016
Therapeutic targets and new directions for antibodies developed for ovarian cancerHeather J Bax, Debra H Josephs, Giulia Pellizzari, et al.
Mabs|September 1, 2025
Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case studyVanessa Siegmund, Daniel Klewinghaus, Jonas Teroerde, et al.
Mabs|May 7, 2020
Hyphenation of strong cation exchange chromatography to native mass spectrometry for high throughput online characterization of charge heterogeneity of therapeutic monoclonal antibodiesFengfei Ma, Fahimeh Raoufi, Marc Andre Bailly, et al.
Mabs|May 14, 2020
Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoiresSamuel Schmitz, Cinque Soto, James E Crowe, et al.
Mabs|June 16, 2015
Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administrationSorina Morar-Mitrica, Manasi Puri, Alexandra Beumer Sassi, et al.
Mabs|July 15, 2016
Phage display-derived human antibodies in clinical development and therapyAndré Frenzel, Thomas Schirrmann, Michael Hust
Mabs|June 4, 2015
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationEwald T J van den Bremer, Frank J Beurskens, Marleen Voorhorst, et al.
Mabs|June 6, 2015
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in miceRyan L Kelly, Tingwan Sun, Tushar Jain, et al.
Mabs|April 11, 2020
Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibodyYan Wang, Donghui Pan, Chenrong Huang, et al.
Pageof 178

Showing results (1461-1470 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|July 16, 2015
MoFvAb: Modeling the Fv region of antibodiesAlexander Bujotzek, Angelika Fuchs, Changtao Qu, et al.
Mabs|August 6, 2016
Therapeutic targets and new directions for antibodies developed for ovarian cancerHeather J Bax, Debra H Josephs, Giulia Pellizzari, et al.
Mabs|September 1, 2025
Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case studyVanessa Siegmund, Daniel Klewinghaus, Jonas Teroerde, et al.
Mabs|May 7, 2020
Hyphenation of strong cation exchange chromatography to native mass spectrometry for high throughput online characterization of charge heterogeneity of therapeutic monoclonal antibodiesFengfei Ma, Fahimeh Raoufi, Marc Andre Bailly, et al.
Mabs|May 14, 2020
Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoiresSamuel Schmitz, Cinque Soto, James E Crowe, et al.
Mabs|June 16, 2015
Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administrationSorina Morar-Mitrica, Manasi Puri, Alexandra Beumer Sassi, et al.
Mabs|July 15, 2016
Phage display-derived human antibodies in clinical development and therapyAndré Frenzel, Thomas Schirrmann, Michael Hust
Mabs|June 4, 2015
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationEwald T J van den Bremer, Frank J Beurskens, Marleen Voorhorst, et al.
Mabs|June 6, 2015
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in miceRyan L Kelly, Tingwan Sun, Tushar Jain, et al.
Mabs|April 11, 2020
Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibodyYan Wang, Donghui Pan, Chenrong Huang, et al.
Pageof 178